Skip to main content

Table 3 Amikacin versus kanamycin use in MDR-TB treatment and the presence or absence of hearing loss

From: Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort

Aminoglycoside exposure Any hearing loss No hearing loss Total
Kanamycin 168 (56 %) 134 (44 %) 302
Amikacin 38 (75 %) 13 (25 %) 51
Total 206 147 353